• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [21797 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2009     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Implementation and development of a treatment programme for peritoneal carcinomatosis in Catalonia. Indications and clinical results using Sugarbaker's technique]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Implantation via injection under endoscopic ultrasound guidance of 32P-labeled microparticles for unresectable, locally advanced pancreatic tumours]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Implantation via injection under endoscopic ultrasound guidance of 32P-labeled microparticles for unresectable, locally advanced pancreatic tumours - Addendum to commission H21-13]
2009     Committee for New Health Technology Assessment (CNHTA) [Implantation technology of autologous chondrocyte using fibrin]
2014     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Implantation of a permanent embolic protection in patients with non-valvular attrial fibrillation in left auricular appendage]
2013     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Implantation of a lumbar artificial endoprosthesis (anuloplasty/anular repair device)]
2012     Institut national d'excellence en sante et en services sociaux (INESSS) [Implantable ventricular assist devices: assessment of evidence and required elements to establish a clinical registry in Québec]
2022     Canary Health Service [Implantable neurostimulation device for the treatment of drug-resistant pediatric epilepsy]
2008     Committee for New Health Technology Assessment (CNHTA) [Implantable drug infusion pump implantation]
2024     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Implantable devices for left atrial appendage closure. Monitoring study]
1999     Andalusian Health Technology Assessment Area (AETSA) [Implantable defibrillators: criteria for clinical indications and decision making on coverage - non-systematic review]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Implantable cardiac monitors in syncope of unknown etiology]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Implantable cardiac defibrillator for primary prevention of sudden death]
2020     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Implantable automatic defibrillator for primary prevention of sudden cardiac death in Spain: efficacy, safety, and efficiency]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Implantable and programmable sacral neuromodulator (Interstim®) treatment of urinary, fecal and combined incontinence]
2009     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Implant-supported supraconstructions for the treatment of shortened dental arches]
2011     Andalusian Health Technology Assessment Area (AETSA) [Impella Recover® 2.5 ventricular assist device]
2016     Basque Office for Health Technology Assessment (OSTEBA) [Impact of the implementation of EFQM in Osakidetza]
2016     Basque Office for Health Technology Assessment (OSTEBA) [Impact of the implementation of a population-based cervical cancer screening program based on European recommendations (test/interval) with regard to the current situation]
2010     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Impact of HTA-research in Austria for the health care system. Part 1: Overview - Update]
2012     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Impact of day care centres in monitoring patients with Obstructive Sleep Apnea Syndrome (OSAS)]
2009     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Impact of clinical and health services research in advancing knowledge. Applied study to the CAHTA research calls]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Impact of clinical and health services research in advancing knowledge. Applied study to the CAHTA research calls (second edition)]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Impact of clinical and health services research calls on informing decision-making and capacity building. The viewpoint of the researchers]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Impact of a prioritization system for patients on waiting list for hip and knee arthroplasties and cataract surgery]
2011     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Impact from HTA-research for the Austrian health care system. Part 2: Results of the empirical survey]
2016     Institut national d'excellence en sante et en services sociaux (INESSS) [Impact evaluation of optimal use guidelines implementation for self-monitoring of blood glucose by adult patients with type 2 diabetes and not using insulin]
2018     Basque Office for Health Technology Assessment (OSTEBA) [Immunological faecal occult blood test for patients with symptoms compatible with colorectal cancer: recommendation of Clinical Practice Guides and use in the National Health System]
2009     The Regional Health Technology Assessment Centre (HTA-centrum) [Immunoglobulin in patients with post-polio syndrome]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Immunoglobulin in chronic inflammatory demyelinating polyneuropathy and other neurological conditions]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Immunoglobulin for myasthenia gravis chronic treatment]
2010     Andalusian Health Technology Assessment Area (AETSA) [Immunogenicity and safety of prepandemic vaccines against H5N1 avian flu]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Immunocyanin in urothelial bladder cancer
2012     Institut national d'excellence en sante et en services sociaux (INESSS) [Immunochemical fecal occult blood. Determination of a positivity threshold for the upcoming demonstration projects under Québec's colorectal cancer screening program]
2010     Andalusian Health Technology Assessment Area (AETSA) [Immunisation against angiotensin II. A therapeutic vaccine against arterial hypertension]
2005     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Immediate breast reconstruction. Systematic review and evaluation of results in a RMI unit in the Community of Madrid]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Imlifidase (kidney transplantation) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Imipenem/cilastatin/relebactam (bacterial infections) - Assessment according to §35a (para. 1c) Social Code Book V]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Imatinib in the treatment of chronic myelogenous leukemia]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Imatinib for gastro-intestinal stromal tumors]
2013     The Regional Health Technology Assessment Centre (HTA-centrum) [Image-guided system for endoscopic sinus surgery]
2022     Basque Office for Health Technology Assessment (OSTEBA) [Image-guided spinal fusion technology]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Image-guided radiosurgery and radiotherapy for central nervous systems tumors]
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Image-guided radiation therapy in liver and lung tumors]
2009     Committee for New Health Technology Assessment (CNHTA) [IL2RG gene mutation analysis]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Idursulfase (Elaprase) in the treatment of mucopolisacaridosis II
2008     Committee for New Health Technology Assessment (CNHTA) [IDUA gene, mutation[sequencing]]
2006     The Netherlands Organisation for Health Research and Development (ZonMw) [Identifying optimal diagnostic strategies algorithms with multiple tests. Ancillary study of Optimisation of diagnostic imaging use in patients with acute abdominal pain: cost-effectiveness analysis of imaging strategies (OPTIMA study)]
2012     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Identifying opportunities for health care disinvestment]
2013     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Identifying ineffective interventions and health technologies: models and their implementation]
2019     Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS) [Identification of psychosocial practices and interventions that support the adaptation and rehabilitation of adults with Prader-Willi Syndrome]
2005     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Identification of preventive health care for children and young people]
2021     Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS) [Identification of factors influencing the risk of absconding in a user with an intellectual disability, autism spectrum disorder or a mental health disorder]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Idelalisib: benefit assessment according to §35a Social Code Book V]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Idelalisib (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Idelalisib (chronic lymphocytic leukaemia) - Addendum to Commission A16-18]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Idelalisib - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Idecabtagene vicleucel (multiple myeloma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Idebenone: assessment according to §35a (para. 1., sentence 10) Social Code Book V]
2012     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Idebenone for the treatment of Friedreich's ataxia]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Idebenone (Leber hereditary optic neuropathy) - assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Icosapent ethyl (hypertriglyceridaemia) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Icosapent ethyl (cardiovascular risk reduction) - Addendum to Commission A21-113]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ibrutinib (previously untreated chronic lymphocytic leukaemia) – Addendum to Commission A23-04]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ibrutinib (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ibrutinib (new therapeutic indication, Waldenstroem macroglobulinaemia) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ibrutinib (new therapeutic indication, chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ibrutinib (CLL) - Benefit assessment according to §35a Social Code Book V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ibrutinib (chronic lymphocytic leukaemia): benefit assessment according to §35a Social Code Book V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ibrutinib (chronic lymphocytic leukaemia): Addendum to Commission A16-39]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ibrutinib (chronic lymphocytic leukaemia, first line) - Benefit assessment according to §35a Social Code Book V]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ibrutinib - Benefit assessment according to §35a Social Code Book V]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ibrutinib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ibrutinib - addendum to commission A16-04]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ibalizumab (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2011     Committee for New Health Technology Assessment (CNHTA) [I-125 permanent implant for prostate cancer]
2008     Finnish Office for Health Care Technology Assessment (Finohta) [Hysteroscopic sterilisation using a metal micro-insert]
2021     Norwegian Institute of Public Health (NIPH) [Hysterectomy for heavy menstrual bleeding: rapid health technology assessment]
2011     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Hypothermia therapy for treatment of neonatal hypoxic-ischemic encephalopathy]
2020     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Hypoglossal nerve stimulation systems for treatment of obstructive sleep apnea]
2014     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Hyperthermic intraperitoneal chemotherapy]
2013     Andalusian Health Technology Assessment Area (AETSA) [Hyperthermic intraperitoneal chemotherapy. Efficacy and safety in the treatment of ovarian cancer peritoneal carcino matosis]
2010     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Hyperthermia]
2020     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Hyperbaric oxygenotherapy for fybromialga, peripheral vascular disease, neurological disease and other indications]
2012     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Hyperbaric oxygen treatment of injuries after radiotherapy for head and neck cancer - a health technology assessment]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Hyperbaric oxygen therapy: Evidence report for the S3 guideline on atraumatic femoral head necrosis in adults]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Hyperbaric oxygen therapy vs. core decompression: Evidence report for the S3 guideline on atraumatic femoral head necrosis in adults]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Hyperbaric oxygen therapy in pseudoarthrosis]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Hyperbaric oxygen therapy in lateral sinus thrombosis]
2020     Norwegian Institute of Public Health (NIPH) [Hyperbaric oxygen therapy for radiation-induced cystitis]
2008     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Hyperbaric oxygen therapy for idiopathic osteonecrosis of the femoral head in adults]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Hyperbaric oxygen therapy for diabetic foot syndrome]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Hyperbaric oxygen therapy for chronic ulcers]
2007     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Hyperbaric oxygen therapy for burns]
2009     Committee for New Health Technology Assessment (CNHTA) [Hyoid myotomy suspension]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Hydrotherapy in skeletal muscle disorders]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Hydrocortisone (adrenal insufficiency) - Benefit assessment according to §35a Social Code Book V]
2013     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Hybrid operating room]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Hyaluronic acid dermal fillers in skin repair procedures]
2009     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Human papillomavirus (HPV) vaccination for the prevention of HPV 16/18 induced cervical cancer and its precursors]